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ABSTRACT
The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An
important part of this research has been focused on randomized controlled clinical trials to evaluate
potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible.
This presents a number of challenges associated with considerable uncertainty over the natural history of
the disease and the number and characteristics of patients affected, and the emergence of new potential
therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such
designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently
strong evidence has been observed to answer the research question, without compromising the trial’s
scientific validity or integrity. In this article, we describe some of the adaptive design approaches that are
available and discuss particular issues and challenges associatedwith their use in the pandemic setting. Our
discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.
ARTICLE HISTORY
Received May 2020
Accepted June 2020
KEYWORDS
Adaptive trial; Group
sequential design; Multi-arm
multi-stage; Pandemic
research; Platform trial;
SARS-CoV-2
1. Background and the Value and Need for Adaptive
Designs
1.1. Introduction
Well conducted high quality randomized controlled clinical
trials are the gold standard when evaluating the potential of a
novel intervention, a standard that should not be compromised
during a pandemic. They are an essential component of an
outbreak response (National Academies of Sciences, Engineer-
ing, and Medicine 2017). Ideally, a rapidly conducted trial will
provide definitive evidence about an intervention, allowing its
immediate wide-spread deployment in the field. A vaccine that
reduces risk of infection has the potential to end an outbreak.
Alternatively, a treatment that improves outcomes in those who
are ill may reduce transmissions by encouraging infected indi-
viduals to visit clinics (to receive treatment), thereby reducing
community spread.
1.2. Context of Trials in a Pandemic
Studies must start quickly to track with the epidemic curve and
enroll enough cases. This poses a particular challenge as trials
therefore need to be initiated and started before the natural his-
tory of the disease is fully understood (Baucher and Fontanarosa
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2020). In the West African Ebola outbreak, clinical trials were
devised, funded, and initiated in record time. However, by the
time most studies opened, the incidence of new cases was drop-
ping and most studies failed to complete enrolment (Thielman
et al. 2016). A similar experience is now repeated in COVID-19
where early trials in China (e.g., Wang et al. 2020) were stopped
prior to reaching the preplanned sample sizes due to dwindling
patient numbers and a large number of separate trials have been
initiated investigating the same treatments. Such experience has
led to some feeling that treatment trials conducted during one
outbreak are about finding therapies to use during subsequent
episodes of the disease, although this is certainly not always the
case.
In the context of a novel infectious disease (such as Ebola
or COVID-19), limited experience with treatment is common
and heterogeneity of patient characteristics makes randomiza-
tion an important tool for establishing intervention efficacy
(Dodd et al. 2016, 2019; Proschan, Dodd, and Price 2016).
Additionally, careful considerations about the endpoints used
in the study are required (Dodd et al. 2020). Despite these
challenges, there exist recent examples of trials that immediately
changed practice such as the rVSV Ebola RING vaccine trial
(Henao-Restrepo et al. 2017) andPALM inEbola (Mulangu et al.
2019).
© 2020 The Author(s). Published with license by Taylor and Francis Group, LLC
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1.3. Aims and Remit of This Article
The recent experience in COVID-19 is that poorly conducted
studies together with a certain degree of desperationmixed with
endorsement of treatments by national and international leaders
have meant that treatments have become widely used despite
limited evidence of either benefit or safety.
This article seeks to make the case that scientific rigor is
equally important during a pandemic outbreak as it usually
is (London and Kimmelman 2020). We highlight the benefits
provided by the flexibility of adaptive designs. Following the
recent CONSORT extension for adaptive designs (Dimairo et al.
2020), we define an adaptive design as “A clinical trial design
that offers preplanned opportunities to use accumulating trial
data to modify aspects of an ongoing trial while preserving
the validity and integrity of that trial.” We provide a guide to
the literature on statistical methods for such designs, briefly
describing the main approaches and giving key references. We
seek to remind readers that one must ensure that possible adap-
tations are considered in the final trial analysis, as some critics
will otherwise raise questions about the scientific integrity of
the study, and definitive trials are meant to resolve, not stir,
controversy. We provide examples of COVID-19 trials that use
different adaptive features and finally discuss some of the more
challenging aspects of implementing adaptive designs during a
major disease outbreak.
2. Examples of COVID-19 Trials With Adaptive
Designs
Adaptive designs have been used (and were planned to be used)
during epidemic outbreaks in the past. During the 2014 Ebola
virus disease outbreak inWestAfrica, for example, the PREVAIL
II trial (Dodd et al. 2016) used a Bayesian sequential design with
non-informative priors (termed “barely Bayesian design”), while
the RAPIDE development platform (Cooper et al. 2015) used
frequentist group-sequential approaches.
To illustrate some of the choices to be made when imple-
menting an adaptive design, and the issues to be considered
when making these choices, this section presents four different
trials in COVID-19. These range in scope considerably, includ-
ing an early (phase I/II) dose-finding platform, a confirmatory
(phase III) trial, and two trials of COVID-19 patients embedded
within previously-running trials. In all cases, an adaptive design
has been employed, the aim of which is to obtain a meaningful
result from the trial as quickly as possible without any loss of
scientific integrity. Our aim in including these examples is not
to give a comprehensive review of COVID-19 research, or even a
full description of each of these four trials, details of which can
be found via the trial registration numbers given, but to high-
light the nature and purpose of the adaptive design approach
used in each case. More detailed descriptions of the different
methodological approaches used for the adaptive designs are
then given in Section 3.
2.1. A Randomized Phase I/II Platform Trial Using a
Bayesian Sequential Phase II Design: The AGILE
Platform (EudraCT 2020-001860-27)
The first example is of a phase I/II dose-finding platform.
Before investigating a new or existing compound in COVID-19
patients in a large efficacy trial, it is essential to establish safe
doses and preliminary signs of activity. The AGILE (Accelerat-
ing COVID-19 Drug Development, EudraCT 2020-001860-27)
trial is a randomized seamless phase I/II trial platform in which
multiple different candidate treatments, potentially in different
populations, can be evaluated. An illustration of the design
is given in Figure 1 with the full protocol given by Griffiths
et al. (2020). Each candidate compound entering the platform
undergoes dose-escalation initially to establish its safety profile.
Safe doses then progress to a Bayesian adaptive group-sequential
(GS, Gsponer et al. 2014) phase in which the efficacy of the
doses is established. For each compound, the trial is seamless in
that the efficacy data observed during the dose-escalation phase
of the trial are used in the efficacy phase, and similarly safety
information from the efficacy phase contributes to the safety
model.
The safety of the doses is defined in terms of the risk of a dose-
limiting toxicity (DLT) in the first 7 days, with dose-escalation
decisions based on a randomized Bayesian model-based design
(Mozgunov, Jaki, and Paoletti 2019). Cohorts of patients are
randomized between the control arm (standard of care, SoC)
and the highest active dose that is safe according to the safety
model. Patients within each cohort are randomized 2:1 in favor
of the active dose. The inclusion of control in the dose-escalation
phase is motivated by the potential overlap between DLTs and
symptoms associated with COVID-19 and the need to avoid
labeling potential treatments as unsafe due to misclassifying
nontreatment related toxicities. Every dose that is found to be
sufficiently safe can proceed to the efficacy evaluation phase so
that it is possible to have several parallel efficacy evaluations of
different doses of the same compound.
The efficacy of a given dose of a compound is established via
a randomized Bayesian GS trial with a time-to-event primary
endpoint. Patients are again randomized 2:1 in favor of the active
dose being studied. The endpoint depends on the population
under study. For mild andmoderate cases, time to negative viral
titers in nose and/or throat swab within 29 days is used while
time to a 2-point improvement in the WHO clinical severity
score (WHOWorking Group on the Clinical Characteristics of
COVID-19 infection 9-point ordinal scale) within 29 days is
used for patients with severe disease. After the efficacy data
are observed, the dose can be (i) dropped for futility; (ii)
progressed to a definitive trial; (iii) be evaluated in an additional
cohort of patients, again randomized 2:1. Stopping is based
on predefined stopping boundaries that have been derived
under a Bayesian GS design such that the Type I error for the
evaluation of each dose is controlled to be below 10%. The GS
trial gains further efficiency by allowing up to 20 concurrent
control observations from other compounds to be shared. The
final analysis for efficacy for each arm is based on a Bayesian
Cox-model with an uninformative prior for the treatment
effect.
2.2. AMulti-ArmMulti-Stage (MAMS) Trial: The
RECOVERY-Respiratory Support Trial
(ISRCTN16912075)
The second example is the RECOVERY-Respiratory Support
trial (ISRCTN16912075). This is a multi-arm multi-stage
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Figure 1. Illustration of AGILE design.
(MAMS) randomized clinical trial to compare three nonin-
vasive ventilation methods of standard care (oxygen given via
face masks or nasal tubes), high flow nasal oxygen (HFNO),
and continuous positive airway pressure (CPAP) for patients
with confirmed or suspected COVID-19 who require oxygen
(FiO2 ≥ 0.4 and SpO2 ≤ 94%). The primary endpoint is the
requirement of intubation or death within 30 days.
The trial team acknowledged that not all centers would be
able to randomize patients between all three arms, for example,
due to the lack of availability of one of the interventions. Tomax-
imize recruitment to the trial it was decided to include centers
provided they could randomize patients between standard care
and at least one of HFNO and CPAP.
The inclusion of centers randomizing between different
interventions gives the potential for bias, for example, due to
differences between centers randomizing to all arms and those
randomizing only to HFNO and standard care. To avoid this
bias, analyses will only compare HFNO patients with standard
care patients from centers that included HFNO patients, and
only compare CPAP patients only with standard care patients
from centers that included CPAP patients. The sample size will
account for this.
The trial started in April 2020 with a target recruitment of
4002 patients from 40 centers. This would give 90% power to
detect a reduction in the proportion of patients requiring intu-
bation or dying from 15% to 10%. To achieve this sample size,
the trial is expected to be completed within 18 months. Given
the urgent need for effective treatments for COVID-19 patients
and the potential long duration of the trial, the investigators
wanted to stop the study early if either CPAP or HFNO was
shown to be more effective than standard care, or to drop an
arm or stop the study completely if one or both experimental
arms was not sufficiently promising. This ability was achieved
through the planning of interim analyses on a monthly basis. A
formal GS stopping rule for efficacy of either experimental arm
over standard care was proposed based on the alpha-spending
function approach (Kim and Demets 1987), as described in
Section 3.3.
The stopping rule is applied separately for each pairwise
comparison with standard care. A conventional one-sided over-
all Type I error rate of 0.025 was used, and the final analysis will
take account of the GS design using the approach proposed by
J. Whitehead (1997). No adjustment is planned for the multi-
ple comparisons with standard care. No futility boundary was
specified, though the trial data monitoring committee (DMC),
who will monitor the data monthly, will be able to recommend
that an experimental arm be dropped or the trial be stopped for
futility at any interim analysis.
2.3. Embedding a Trial Within a Trial: The CAPE-Covid and
the CAPE-Cod (Community-Acquired Pneumonia:
Evaluation of Corticosteroids) Studies (NCT02517489)
The third example shows how an existing trial was modified
to include an embedded trial of COVID-19 patients, with
this embedded trial given a GS design. The CAPE-Cod trial
(NCT02517489), assessing the efficacy of hydrocortisone to
improve 28 day survival in intensive care units (ICU) for
patients suffering severe community-acquired pneumonia
(CAP), was active and recruiting patients at the beginning of
the COVID-19 pandemic. As SARS-CoV-2 pneumonia was not
an exclusion criterion of the CAPE-Cod trial, centers started to
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Figure 2. REMAP-CAP trial structure for COVID-19 patients (adapted from a webinar by Berry Consultants, https://www.youtube.com/watch?v=mhPsj1j3hlk).
include COVID-19 infected patients in the study. As the clinical
characteristics of the two indications differ, trial stakeholders
have decided to study the COVID-19 patients by embedding
a specific study considering the COVID-19 indication only,
with the CAPE-Cod study interrupted temporarily to account
for patients’ heterogeneity in disease characteristics and
evolution.
A GS design using the alpha-spending approach (Kim and
Demets 1987) was used for the embedded COVID-19 study.
This was chosen for its simplicity in terms of training the
local methodological team, availability of software and medical
community acceptance of study results. A conservative stopping
boundary was selected for efficacy with an aggressive boundary
for futility; that is stopping for superiority only if the evidence
is particularly strong while stopping early if the experimental
treatment is not sufficiently promising. This will be adjusted
for in the final analysis. A blinded sample size re-estimation
was included in the study protocol because of uncertainty about
the mortality rate for placebo patients with COVID-19, with
estimates ranging from 26% to 73% (Grasselli et al. 2020; Ruan
et al. 2020).
2.4. Evaluating COVID-19 Treatments in anOngoing
Adaptive Platform Trial: The REMAP-CAP Trial
(NCT0273570)
The final example is of a trial that was designed to be
able to adapt to an acute pandemic need. Motivated by the
2009 swine flu (H1N1) pandemic, the Randomized, Embed-
ded, Multifactorial Adaptive Platform trial for Community-
Acquired Pneumonia (REMAP-CAP, NCT0273570) seeks to:
(i) evaluate multiple interventions to improve outcomes of
patients admitted to an ICU with severe CAP, and (ii) provide a
platform that can respond rapidly in the event of a respiratory
pandemic.
The primary endpoint for COVID-19 patients entering
REMAP-CAP is a composite of in-hospital death and the
number of ICU free days over 21 days, thus forming a 23-point
ordinal scale, that is, -1 (death), 0, 1, …, 21. Adult patients
with suspected or proven COVID-19 are enrolled into the
COVID-19 stratum of REMAP-CAP, on an open-label basis,
and classified into severe (in ICU) or moderate (hospitalized
but not in ICU) disease states.
Within each disease state, there aremultiple domains, each of
which is a set of mutually exclusive interventions. An example
is the antiviral domain comprising four interventions: (1) no
antiviral; (2) lopinavir/ritonavir; (3) hydroxychloroquine; (4)
lopinavir/ritonavir and hydroxychloroquine combination. The
trial is adaptive so that new domains or interventions can be
added at any time. Sites do not necessarily need to include all
of the available domains or interventions.
Each patient is randomized to a regimen—one intervention
from every domain—so that they receive multiple interventions
simultaneously; this forms the multifactorial component of the
trial design (Figure 2). By randomizing patients to multiple
interventions, only a few receive no active treatment. Response-
adaptive randomization is used to allocate patients to regimens
so that more patients receive the most promising regimen(s) as
the trial progresses.
Interim analyses occur frequently and are currently expected
to take place weekly, although this will fluctuate with the rate of
enrolment. They are also used to detect superiority, inferiority,
or equivalence of interventions. Depending on regional differ-
ences or treatment availability, for example, an interventionmay
not necessarily be dropped if it is needed in the pandemic.
All inferences in this trial are based on a Bayesian statistical
model, which estimates the posterior probability of the primary
endpoint for each regimen and takes into account the variation
in outcomes by region, stratum, disease state, age group, and
time since the start of the trial. The full statistical analysis plan
is available at https://www.remapcap.org/protocol-documents.
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3. Statistical Principles of Adaptive Design
3.1. Motivation for Using Adaptive DesignMethods
Traditionally, clinical trials testing one or more null hypothe-
ses have followed nonadaptive designs where all details of the
design are specified ahead of time. In recent decades, however,
there has been a rise of adaptive designs for clinical trials in
all phases of drug development (Pallmann et al. 2018) and, in
response, regulatory authorities have issued several guidelines
for adaptive designs (European Medicines Agency 2007; Food
and Drug Administration 2019).
Suppose we want to perform a clinical trial to test whether
an experimental treatment is superior to control (placebo or
current SoC). Measuring the benefit of the novel treatment
over control by θ , we want to test the one-sided null hypoth-
esis H0: θ ≤ 0 versus the alternative H1: θ > 0. To claim
control of the Type I error rate for the trial, the probability of
incorrectly rejecting H0 must not exceed a prespecified level α.
The need to maintain strict control of the Type I error rate is
well established, particularly in the context of late-phase studies
(EuropeanMedicines Agency 1998) where a typical choice for α
is 0.025. In many situations, however, clinical trials have several
objectives. For example, trialists may want to compare several
experimental treatments or active doses with control, or evalu-
ate the effect of a novel treatment in several patient subgroups. In
this setting, a trial begins testingm null hypotheses H0i: θi ≤ 0,
for i = 1, . . . ,m, and often is designed to maintain strong
control of the family-wise error rate (FWER) at some level α,
which is achieved if the probability of rejecting one ormore true
null hypotheses does not exceed α. The requirement to control
the FWER is similar to that of controlling the Type I error rate
in that it restricts the probability of making a false claim of
efficacy.
Why should one use an adaptive design in the first place?
When planning a clinical trial there might be (substantial)
uncertainty about important design parameters, for example,
which effect sizes and value of the outcome variance are realistic
and in which study population. If the study population is
set too broadly, or the assumed variance is too small, the
study will be underpowered. To address such uncertainties,
it is tempting to learn from accumulating data and adapt if
necessary. Adaptations of interest for COVID-19 trials may
include early stopping for futility or efficacy at an interim
analysis, sample size reassessment, dose-group selection, change
of allocation ratio or modification of the study population in a
data dependent way. Emerging knowledge of the natural history
of COVID-19 can also make the choice of a primary endpoint
for a trial difficult (Dodd et al. 2020). Adaptive methods are
available to enable a change in endpoint (Kieser, Bauer, and
Lehmacher 1999), though it is important to ensure that the
results of a trial will be sufficiently convincing to the scientific
community when making such a change.
MAMS designs (e.g., Stallard and Friede 2008; Magirr, Jaki,
and Whitehead 2012; Wason et al. 2016) are of great interest
for COVID-19 trials. They increase efficiency by comparing
multiple experimental treatments against a shared control group
(Parmar, Carpenter, and Sydes 2014), while the adaptive design
allows early stopping of nonpromising (or highly efficacious)
arms using prespecified decision rules (Wason and Jaki 2012).
Platform trial designs (Meyer et al. 2020) allow new experimen-
tal treatments to be added as the trial progresses and often start
as, or become, MAMS trials. Platform trials provide notable
operational efficiency (Schiavone et al. 2019) since evaluation
of a new treatment within an existing trial will typically be
much quicker than setting up a new trial. This flexible approach
enabled the REMAP-CAP trial described in Section 2.4 to
rapidly be adapted to study COVID-19 patients. Platform trials
are cited as one potential approach for evaluating drugs intended
to treat or prevent COVID-19 in a recent guidance (Food and
Drug Administration 2020) and several other platform trials,
such as the SOLIDARITY trial (ISRCTN83971151) and the
RECOVERY trial (ISRCTN50189673, www.recoverytrial.net),
are currently running.
For a more detailed review of adaptive clinical trial designs,
we refer the interested reader to Bauer et al. (2016) and Pall-
mann et al. (2018), and the references therein. For a technical
description of the methods for confirmatory clinical trials, we
refer to the book of Wassmer and Brannath (2016). For an
overview of Bayesian adaptive methods, which have attracted
much attention in the context of exploratory trials, see Berry
et al. (2010).
For all adaptive design approaches, data dependent changes
may introduce bias and, particularly for late stage trials, appro-
priate statistical methods must be used to preserve the Type I
error rate. More details on methods to ensure error rate control
is maintained are given in the next sections, with estimation
methods discussed in Section 3.5.
3.2. Type I Error Rate Control in Adaptive Designs
All regulatory guidelines emphasize that, for confirmatory clin-
ical trials following an adaptive design, control of the Type I
error rate is paramount. This requirement remains for trials of
COVID-19 treatments (Food and Drug Administration 2020).
Elsäßer et al. (2014) reviewed scientific advice given by the Euro-
pean Medicines Agency (EMA) on adaptive design proposals
and their outcomes (Collignon et al. 2018). The authors showed
that if adaptive designs are properly implemented, then such
innovative designs are well accepted by health authorities.
Strict control of the Type I error rate can be achieved by using
prespecified adaptation rules such as early stopping boundaries
in GS designs (Jennison and Turnbull 1999) or blinded sample
size reassessment rules when estimating nuisance parameters
at an interim analysis (Friede and Kieser 2006). However, pre-
specified designs do not permit unplanned modifications. To
allow for further flexibility, fully adaptive designs have been
suggested which allow adaptations not completely specified in
the adaptation rule while still controlling the Type I error rate.
Many designs of this type use p-value combination tests (Bauer
and Köhne 1994) to allow for more flexible decision making,
while still preserving the integrity of the design. Alternatively,
designs can follow the conditional error principle (Proschan
and Hunsberger 1995; Müller and Schäfer 2004) to control the
Type I error rate. The conditional error principle enables one
to introduce flexibility to any type of predefined design, even if
no interim analysis was originally planned (Müller and Schäfer
2004); the key is that the significance level of the adapted trial
6 N. STALLARD ET AL.
must not exceed the level of the initial design conditional on
the data already observed. If data are combined across stages of
the adaptive trial using the inverse normal function proposed
by Lehmacher and Wassmer (1999) and Cui, Hung, and Wang
(1999), and monitored against GS boundaries, the test decision
should coincide with the study outcome had no unplanned
adaptation been performed.
If more than one null hypothesis is to be tested, for example,
in a multi-arm study, several extensions (Bauer and Kieser
1999; Hommel 2001) to the designs discussed above have been
proposed which use adaptive designs within a closed testing
framework (Marcus, Peritz, and Gabriel 1976). A closed test-
ing procedure requires level α tests of each individual null
hypothesis to be specified, as well as level α tests of all possible
intersections of null hypotheses; if all tests involving a specific
hypothesis are significant at level α, then that null hypothesis
may be rejected globally at level α. Tests maintaining strong
control of the FWER must (whether explicitly defined or not)
be a closed testing procedure. For adaptive trials, for each null
hypothesis, whether individual or an intersection, an adaptive
test is prespecified.
The advantage of the fully adaptive design is that both inter-
nal and external information can be used to adapt the trial
without fully specifying the adaptation rule. This is crucial in
the pandemic situation as it means emerging data from parallel
trials can be easily incorporated into the adaptation decision
rule of an ongoing adaptive trial without compromising its
integrity.
The methods discussed above focus on ensuring Type I
error rate control in a frequentist setting. It is also possible to
incorporate Bayesian methodology into the decision making
process for adaptations without compromising error rate con-
trol, often using simulation methods to select critical values
and other design parameters (Schmidli, Bretz, and Racine-Poon
2007; Brannath et al. 2009; Berry et al. 2011; Yu, Ramakrishnan,
and Meinzer 2019; Stallard et al. 2020). Such an approach is
illustrated by the examples in Sections 2.1 and 2.4.
3.3. GS Stopping Rules in Confirmatory Adaptive Design
Trials
Incorporating a GS stopping rule into a confirmatory clinical
trial allows for greater flexibility as compared to a standard
trial design without any interim data looks. If an extraordi-
narily large benefit of the experimental treatment over control
is observed at an interim analysis, it is desirable to have the
option to stop the trial for efficacy with early rejection of the
null hypothesis. If such an option is incorporated, a multiple
testing problem emergeswhich needs to be handled by adjusting
the local significance levels for the interim and final analysis to
maintain the nominal Type I error rate. In GS trials with one or
more interim looks, this can be done by using adjusted rejection
regions tailored to prespecified interim analysis times (O’Brien
and Fleming 1979; J. Whitehead 1997). In practice, many GS
trials are run allowing flexibility with regards to the timing and
number of interim analyses, using the alpha-spending function
approach (Kim andDemets 1987) or flexible boundarymethods
(J.Whitehead 1997, 2011). The two examples described above in
Sections 2.2 and 2.3 that are based on frequentist analyses both
use the alpha-spending function approach to ensure that Type
I error rates are controlled. GS stopping rules for efficacy can
also be incorporated in adaptive designs using a combination
test approach (Bauer andKöhne 1994; Lehmacher andWassmer
1999) or the conditional error principle (Proschan and Huns-
berger 1995; Müller and Schäfer 2004).
Alternatively, one might also consider stopping a confir-
matory trial early for futility if data are consistent with clini-
cally irrelevant or harmful treatment effects. Allowing stopping
for futility can be particularly useful in confirmatory trials of
COVID-19 treatments which, due to high levels of unmet med-
ical need,may follow accelerated development programs, so that
limited phase II data are available before the confirmatory study
begins (Food and Drug Administration 2020). Stopping for
futility also means that resources can be quickly diverted to test
more promising interventions. If recruitment into a COVID-
19 trial is rapid, many patients will already have been enrolled
by the time the futility interim analysis is performed, and the
reductions in expected sample size possible by testing group
sequentially will be smaller than those typically cited (Hamp-
son and Jennison 2013). To mitigate this issue, accrual could
be paused in the run-up to a futility interim analysis (Food
and Drug Administration 2020) although in practice restarting
recruitment is very challenging. A futility rule can either be
binding in the sense that it needs to be strictly adhered to at
the interim analysis, or nonbinding, meaning that the rule may
also not be followed. While binding futility rules allow for a
relaxation of the local significance levels, nonbinding rules can
be regarded as more advantageous from a practical perspective
due to their increased flexibility. However, the Type II error rate
increases with the use of a nonbinding futility rule, requiring an
increased sample size to achieve the target power. The COVID-
19 trial examples given above include both trials with binding
(Section 2.3) and nonbinding (Section 2.2) futility stopping
rules.
3.4. Multi-ArmMulti-Stage (MAMS) and Platform Trials
MAMS designs allow several experimental treatments to be
assessed in a single trial with treatments dropped from the trial
as soon as interim analysis data suggest they are ineffective. The
design requires specification of stopping boundaries prior to the
trial starting: these usually consist of futility stopping bound-
aries and, less commonly, efficacy stopping boundaries. At an
interim analysis, each experimental arm is compared against
control using all patients with outcome information up to that
point: experimental arms with test statistics below the futility
boundary have further recruitment stopped and experimental
arms with test statistics above the efficacy boundary can be
concluded to be effective (and the respective null hypothesis
rejected). Setting stopping boundaries is not trivial, but can
be done using analytical formulas (Royston, Parmar, and Qian
2003; Magirr, Jaki, and Whitehead 2012) or simulation in the
frequentist (Wason and Jaki 2012) or Bayesian (Yu, Ramakrish-
nan, and Meinzer 2019) settings. Software exists such as the R
packageMAMS (Jaki, Pallmann, andMagirr 2019) and the Stata
module nstage (Bratton, Choodari-Oskooei, andRoyston 2015).
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The stopping and selection rules are preplanned, meaning that
the trial must be conducted according to the prespecified rules.
A frequentist MAMS design is being used in the COVID-19
RECOVERY-Respiratory Support trial described in Section 2.2.
The design is efficient in that two experimental treatments are
compared with a shared control group with the chance to stop
as soon as sufficiently positive results have been observed or
to drop an arm or stop the trial completely if results are not
sufficiently promising.
The MAMS trial methodology can be generalized to a flex-
ible confirmatory adaptive approach (Magirr, Stallard, and Jaki
2014) which is usually based on the combination testing princi-
ple (Bauer and Köhne 1994). This principle can be applied for
testingmultiple hypotheses by use of the closed testing principle
(Bauer and Köhne 1994; Bretz et al. 2009; Bauer et al. 2016;
Wassmer and Brannath 2016). An application is the multi-arm
setting where, for example, treatment arms can be selected and
sample sizes for the selected treatment arms can be recalcu-
lated based on the observed response (Bauer and Kieser 1999;
Koenig et al. 2008; Magirr, Stallard, and Jaki 2014; Wassmer
and Brannath 2016). For these designs, the adaptation rules,
need not be prespecified. Consequently, this approach allows for
testing in MAMS trials controlling the FWER in a strong sense.
R packages are available for confirmatory adaptive designs in
the multi-arm setting, such as asd (Friede, Stallard, and Parsons
2020) and rpact (rpact 2020), with MAMS (Jaki, Pallmann,
and Magirr 2019) also having an extension for dealing with
unexpected design modifications.
Some MAMS trials use adaptive randomization (AR) to
guide allocation to better performing arms. In a multi-arm
setting, if the shared control group is kept separate from the
AR procedure, this maintains the power at a high level (Wason
and Trippa 2014; Williamson and Villar 2020). Frequentist and
Bayesian approaches to AR can be used, although in practice it
is more common to use a Bayesian approach, as in the REMAP-
CAP trial described in Section 2.4. AR has been criticized for
being susceptible to temporal trends in the trial (Thall, Fox, and
Wathen 2015; Proschan and Evans 2020), whichmay be possible
in COVID-19 settings due to mutation of the virus. However, if
the allocation to the shared control group is maintained, there
is little impact on the statistical properties of the trial (Villar,
Bowden, and Wason 2018).
Another type of MAMS design is the drop-the-losers design
(Sampson and Sill 2005; Wason et al. 2017), which sets a
fixed number of arms to progress at each interim analysis. An
advantage of this is that the design has a fixed sample size (in
contrast to a random sample size for the approach described
above). The main disadvantage is that it may lead to dropping
of promising arms if there are more than the design is permitted
to take forward. Approaches that combine the drop-the-losers
approach with prespecified stopping boundaries have been
proposed (Friede and Stallard 2008) to allow early stopping
for futility and efficacy.
Magirr, Jaki, andWhitehead (2012), Wason et al. (2017), and
Robertson and Wason (2019) describe how FWER control can
be achieve in a MAMS design. However, there has been debate
about which type of multiplicity adjustment, for example, pair-
wise or family-wise, is needed for a multi-armed design (e.g.,
Wason, Stecher, andMander 2014; Stallard et al. 2019; Collignon
et al. 2020). Generally, the decision will be determined by the
relative importance of making a Type I error and a Type II
error, as correcting for multiple testing reduces the power. In
a platform setting, it is more difficult to formally control the
FWER unless it is known in advance how many treatments will
be tested. New methods for online control of error rates may
provide a way of doing this if it is required (Robertson and
Wason 2018).
Most methodology work in MAMS has focused on settings
with a shared control group. In the case of no obvious control
group, we would refer the reader to theMagaret et al. (2016) and
the motivating example in Whitehead, Desai, and Jaki (2020).
When there is a shared control group, the relative alloca-
tion between control and experimental treatments can affect
the power. A natural choice is to randomize patients equally
between each available treatment. One can gain a small amount
of power by increasing the allocation to the control group (Wass-
mer 2011; Wason et al. 2016), although in a MAMS study the
optimal allocation depends on the likelihood of dropping arms
only. Setting the allocation ratio of new arms in a platform study
can also be optimized (Bennett and Mander 2020).
3.5. Estimation After an Adaptive Design Trial
Point estimates and confidence intervals (CIs) for the treatment
effects assessed in a confirmatory clinical trial play a key role
in deciding whether or not to recommend adoption of the
new interventions in clinical practice. Therefore, the estimators
used in confirmatory adaptive clinical trials need to have good
accuracy. In some settings conventional estimation approaches
may be used provided the bias can be shown to be small. In
other settings naive point estimators that assume a two-arm
single-stage design can be substantially biased for an adaptive
trial because of the possibility of stopping early for futility or
overwhelming effect (Whitehead 1986; Koopmeiners, Feng, and
Pepe 2012) and/or selecting the most promising experimental
treatments at an interim analysis (Bauer et al. 2010; Carreras
and Brannath 2013; Kimani, Todd, and Stallard 2013). For two-
stage trials, conditional on the trial continuing to stage 2, the
selection rule and the treatments continuing to stage 2, several
uniformly minimum variance conditional unbiased estimators
(UMVCUEs) exist (Bowden and Glimm 2008; Kimani, Todd,
and Stallard 2013; Robertson, Prevost, and Bowden 2016; Stal-
lard and Kimani 2018). The UMVCUEs can have large mean
squared errors (MSEs) and are computed if the trial continues
to stage 2. Alternative shrinkage estimators that are based on
empirical Bayes approaches tend to have smaller MSEs but
they are not necessarily unbiased (Carreras and Brannath 2013;
Brückner, Titman, and Jaki 2017). Estimators that also reduce
bias when a trial stops in stage 1 exist (e.g., Stallard and Todd
2005; Carreras and Brannath 2013) as well as generalizations to
multiple stages (Whitehead, Desai, and Jaki 2020).
Naive CIs can have incorrect coverage. When an adaptive
design selects themost effective experimental treatment in stage
1, among the methods that adjust for adaptation (Sampson
and Sill 2005; Stallard and Todd 2005; Wu, Wang, and Yang
2010; Magirr et al. 2013), the Sampson and Sill (2005) method
performs best in terms of coverage while the approach of Wu,
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Wang, and Yang (2010) is the most straightforward for com-
puting CIs (Kimani, Todd, and Stallard 2014). Methods for
computing CIs with other selection rules are available (Neal
et al. 2011; Magirr et al. 2013). One of these methods allows
continuing withmultiple experimental treatments in stage 2 but
sometimes the computed CIs are non-informative (Magirr et al.
2013).
Most of themethods above assume normally distributed out-
comes with known variance. Extensions to the case of unknown
variance (Robertson and Glimm 2019) exist and, using asymp-
totic approximations, they can be extended to other outcomes.
Point estimation with time-to-event outcomes has been con-
sidered separately as these outcomes pose specific challenges
(Brückner, Titman, and Jaki 2017). One of the UMVCUEs is a
generalization of the others enabling MAMS trials (Stallard and
Kimani 2018).
4. Specific Statistical Issues in Adaptive Designs in
COVID-19 Intervention Trials
4.1. Characterizing the Dose–Response Relationship
When studying a compound in a completely new disease popu-
lation, such as COVID-19, it is essential to identify a therapeutic
window, that is, a range of doses which simultaneously control
the risk of adverse events while having a clinically meaning-
ful efficacy effect. Importantly, the same requirement applies
to repurposed medicines as the dose selected for the original
indication is not guaranteed to be optimal for the COVID-19
population. Characterization of the dose–response relationship,
however, poses several statistical challenges.
Both the toxicity and efficacy signals should be attributable
to the compound rather than to the baseline toxicity and effi-
cacy rates. Therefore, the dose–response relationship should
be established accounting for outcomes on control, by quan-
tifying differences between the active doses and control (SoC
or placebo) for both toxicity and efficacy endpoints. Further-
more, to gain efficiency by using data across different doses
of the compound, a model-based approach that stipulates a
parametric relationship for the underlying differences should
be used. This, in turn, poses a challenge in terms of how to
select the dose–response model. To overcome this, an MCP-
Mod approachwhich considers several candidatemodels (Bretz,
Pinheiro, and Branson 2005; Pinheiro et al. 2014), or a model-
averaging approach can be used. To establish the dose-response
relationship, randomization of patients between doses is needed
to allow for efficient dose-response estimation. Consequently,
the safety of the dosing range must be established before the
dose-response relationship can be reliable characterized. A two-
stage procedure adjusting allocation probabilities to each dose
could also be used (Mielke and Dragalin 2017).
To ensure the most efficient use of the data, the most infor-
mative yet clinicallymeaningful endpoint should be used.While
it is common to dichotomize continuous or time-to-recovery
endpoints to simplify the analysis, it is inevitable that this will
result in the loss of some statistical information; specifically,
this strategy has been found to result in noticeable losses when
characterizing the dose–response relationship (Mozgunov, Jaki,
and Paoletti 2020). While dose–response models for contin-
uous and binary endpoints are more common, there are also
parametric and semiparametric models available for time-to-
event data with implementations available in standard statistical
software.
In the AGILE trial described in Section 2.1 the risk of toxicity
(yes/no) ismodeled and excess risk of toxicity of the investigated
treatment above control is used for dose-selection.
4.2. Choice of Primary Endpoint
Choosing the primary endpoint is often a challenge in clinical
trials, but a novel disease with lots of uncertainty makes this
choice is even more challenging. Whitehead and Horby (2017)
approached this challenge by recognizing that outcomes such
as recovered versus not recovered are almost always of interest.
In recent work discussing different choices of endpoints for
COVID-19, Dodd et al. (2020) also state that mortality is a
desirable endpoint for COVID-19 that might be difficult to use
in practice due to the large number of patients required. Other
endpoints are therefore often used, but as knowledge about the
disease increases, alternative endpoints might emerge that are
deemed to be more suitable. In such a situation it is natural
to want to adapt the primary endpoint in the light of this new
information. Such an approach is possible within an adaptive
design (Kieser, Bauer, and Lehmacher 1999), but challengesmay
arise in convincing end-users of the trial results that such a
change have not been made with ill intent. A recent example of
a trial that did change the primary endpoint is the ACTT trial
(Beigel et al. 2020) that initially used the WHO ordinal scale at
a fixed time point but later changed, on the basis of information
external to the trial, to time-to-recovery.
4.3. Stopping a Trial Early Due to Recruitment Difficulties
The incidence of COVID-19 will vary over the course of the
pandemic. A trial starting recruitment during the “post-peak”
phase of the pandemic, as disease activity levels trail off, may
struggle to reach the target information level before it ends. If
a GS test is stopped early due to feasibility issues, steps can be
taken to draw valid inferences about the target treatment effect.
As mentioned in Section 3.3, many GS trials are monitored
according to the alpha-spending function approach (Kim and
Demets 1987), and accommodating early termination in this
framework is relatively straightforward. At the final analysis,
we choose the critical value of the test so as to “spend” all the
remaining Type I error rate. Choosing the final critical value in
this way preserves the Type I error rate of the trial, although
there will be a drop in power relative to the originally planned
design. CIs and p-values based on the stagewise ordering of
the test’s outcome space can be calculated conditioning on the
observed sequence of information levels using the methods
described in Section 3.5. A similar idea can be used to reach
a final hypothesis decision in a GS trial which does not follow
an alpha-spending design: one finds the critical value for the
final analysis so that the trial has Type I error rate α given
the observed information levels and the test boundaries used
at previous interim analyses. One additional caveat that applies
to all GS trials stopped early for lack of feasibility: while the
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decision of when to truncate the GS test can (and should)
be informed by trends in recruitment rates, the timing of the
final analysis should not be influenced by previous treatment
effect estimates (Jennison and Turnbull 1999). If, for example,
we bring forward the final analysis because we were close to
crossing a boundary at the last interim look, test statistics will
not follow the anticipated canonical joint distribution used to
calculate stopping boundaries (Jennison and Turnbull 1997),
leading to deviations from the nominal Type I error rate.
If the pandemic ends earlier in some geographic regions
than others, the sponsor of a global study can compensate by
switching to recruit more patients at sites where the disease
is still active. While this strategy would preserve the Type II
error rate of the trial, one would still see perturbations in the
power of region-specific subgroup analyses. In addition, the
impact of this shift in recruitment on the interpretation of the
trial should be carefully considered, particularly if the target
estimand (ICH 2020) remains as the effect of treatment in a
global patient population (which would still be pertinent if all
regions remained at risk of subsequent waves of infection). To
align with this target estimand, the analyst could perform a
random effects meta-analysis of region-specific treatment effect
estimates, where the mean of the random-effects distribution
would be taken as the overall treatment effect of interest.
4.4. Heterogeneity of the Patient Population
The prognosis of COVID-19 is highly variable, ranging from
nonsymptomatic courses of the disease in the majority of
patients, to severe clinical courses requiring hospitalization,
intensive care and leading to death in many cases. A number
of prognostic factors have been identified, including age,
sex, chronic lung disease, diabetes, hypertension, and other
cardiovascular comorbidities (Grasselli et al. 2020; Zhou
et al. 2020). In addition, the time span and course of the
disease up to the time of study inclusion is prognostic for the
outcome. For the design of clinical trials this implies that the
inclusion criteria have a strong impact on the distribution of the
primary endpoint and the corresponding sample size planning.
Furthermore, in the analysis of the clinical trial, the precision
of treatment effect estimates can be substantially improved by
adjusting for important covariates in the analysis. Also, stratified
randomization according to the risk factors can improve the
efficiency of the design.
An important question is to what extent the prognostic fac-
tors are also predictive for the efficacy of the treatment. For
example, for anti-viral drugs it is usually assumed that effi-
cacy is largest when treatment starts early after infection. How-
ever, comorbidities and demographic variables can also play
a role in the mechanism of action or affect the safety pro-
file. If the treatment effect varies across subgroups that are
defined by baseline characteristics, treatment effect estimates
are only meaningful for a well-defined patient population. In
addition, subgroup analyses will be critical to better understand
the treatment effect. Challenges are the typically small sample
sizes in subgroups and the multiplicity problem connected with
multiple analyses. Adaptive enrichment designs can be a useful
tool in this context (see, e.g., Friede, Stallard, and Parsons 2020
for a recent overview). Based on interim results, they allow
one to increase the sample size in specific subgroups or to
restrict randomization to these populations, while controlling
frequentist error rates (Ondra et al. 2016, 2019; Chiu et al.
2018). However, pre-specification of subgroups can be difficult,
especially for quantitative predictive factors (e.g., time from the
onset of the disease), where thresholds need to be prespecified to
define the corresponding sub-populations. If there is not enough
prior information to select a single threshold, subgroup analyses
with multiple thresholds can be implemented if an appropriate
adjustment for multiple testing is foreseen (Graf et al. 2020).
4.5. Dynamically Changing Standard of Care
SoC is likely to evolve quickly in the early stages of a pandemic,
particularly of a previously unknown disease such as COVID-
19, as clinicians’ understanding of the disease and experience
treating it increases rapidly. Of course, many trials in an acute
pandemic setting recruit quickly and measure short-term end-
points; see, for example, the primary endpoints of the RECOV-
ERY and REMAP-CAP trials described in Section 2. Thismeans
that SoC would be expected to remain relatively stable over
the course of an individual study. However, more substantial
changes may be seen over the course of a trial measuring the
long-term outcomes of patients with less severe disease at base-
line. Alternatively, we may see changes in SoC across the course
of several successive studies which we intend to combine via
meta-analysis.
For trials of add-on treatments (comparing SoC+ novel ther-
apy vs. SoC alone), block-randomization or pre-specification
of the allocation probabilities in a parallel group study will be
sufficient to ensure control of the Type I error rate at the nominal
level. If changes in SoC result in a time-varying treatment effect,
the study investigators should consider what the target estimand
is, that is, an aggregate treatment effect averaging across the
course of the study, or the effect of treatment compared with the
most recent version of SoC, and whether the target effect can be
estimated.
Changes in SoC can present a particular challenge in a plat-
form trial adding in new experimental treatments over time. In
this setting, there is debate about whether one should use non-
concurrent control patients in the evaluation of experimental
treatments. If a new treatment is added in part-way through
the trial, concurrent control patients are those who are recruited
from that time; nonconcurrent controls would be those patients
recruited prior to the addition. If it is likely that there is strong
potential for a temporal trend in the data, as may be the case in
COVID-19 trials, it is likely best to use only concurrent controls
as the primary analysis.
4.6. Leveraging Information Across Trials Using
Meta-Analytic Approaches
Comparison-specific treatment effects may accumulate over
the course of a pandemic as randomized controlled trials are
replicated by different research groups, and as platform trials
with common treatment arms report pairwise comparisons.
While theremay be substantial heterogeneity among the control
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groups of successive trials in a pandemic due to the evolving SoC
(Dodd et al. 2019), two-group comparative effects may remain
more stable. Combining evidence across studies in a meta-
analysis will increase the statistical information available for
estimating a target treatment effect. If we prospectively intend
to update the meta-analysis as each new study is published,
the cumulative results should be monitored using a GS test
to avoid over-interpretation of random highs and lows in
treatment effect estimates, and inflation of the Type I and
Type II error rates. Different approaches have been proposed
for monitoring a cumulative meta-analysis (Simmonds et al.
2017). Sequential meta-analysis approaches use GS boundaries
to monitor standardized Z statistics obtained from random-
effects meta-analyses. For example, boundaries could be from
a triangular GS test (A. Whitehead 1997) or a restricted
procedure (Higgins, Whitehead, and Simmonds 2011), or
an alpha-spending test spending Type I error as a function
of the estimated proportion of the target information level
accumulated thus far. The DerSimonian and Laird (1986)
estimate of the between-study heterogeneity may be unstable in
the early stages of a cumulative meta-analysis when few studies
are available, so that estimated information levels may decrease
between successive interim analyses (Higgins, Whitehead,
and Simmonds 2011). With (very) few studies also Bayesian
approaches with weakly informative priors for the between-
study heterogeneity were found to bemore robust than standard
methods (Friede et al. 2017). It may be possible to reduce
between-study heterogeneity and increase borrowing across
studies by leveraging data on baseline covariates, either in a
meta-regression approach if only aggregate data are available
(Neuenschwander and Schmidli 2020), or in models for patient
responses if individual patient data are available.
5. Practical Issues in Conducting Adaptive Designs
As highlighted in Section 1, time is essential when conducting
clinical trials during a disease outbreak. When conducting an
adaptive trial, one particular aspect, namely decision making
about undertaking any of the (preplanned) adaptations, needs
to be particularly considered in addition. This time-sensitivity
means that the decision processes (which often involve review
of unblinded data) are streamlined and decision making is clear
before undertaking any interim data looks to avoid potential
delays in implementing decisions. The DMC of the trial will
often have a particularly crucial role to play in these decision
processes.
5.1. DataMonitoring Committees for an Adaptive Trial
A DMC, also known as data safety monitoring board (DSMB)
or data safety monitoring committee (DSMC), is “a commit-
tee created by a sponsor to provide independent review of
accumulating safety and efficacy data” (Herson 2009). There-
fore, the DMC is “responsible for […] protecting trial integrity
and patient safety” (Herson 2009). Although all trials require
safety monitoring, this does not mean that a DMC needs to
be established for all trials. However, safety monitoring by a
DMC is recommended “for any controlled trial of any size that
will compare rates of mortality or major morbidity” or more
specifically for a “population at elevated risk of death or other
serious outcomes, even when the study objective addresses a
lesser endpoint” (Food and Drug Administration 2006), which
is likely to be the case for any COVID-19 trial. Compared to
other studies, COVID-19 trials might be shorter with faster
recruitment (given the pandemic situation) and shorter length
of follow-up (e.g., restricted to length of stay in hospital). For
safety monitoring by a DMC this, in turn, requires shorter
review intervals, which might lead to weekly safety reviews in
some instances. This has obvious consequences for logistics in
terms of data management, statistical analyses, as well as the
required availability and commitment of the DMC members.
Given these demands it might be practical to set up committees
to monitor not only an individual trial but to oversee several
trials on a programme level. This would not be uncommon
for trials investigating the same compound, but in COVID-19
might be applied also to settings where different compounds are
being investigated by the same sponsor. This would also enable
the DMC to consider data emerging from other ongoing trials
in their decision making, allowing them to integrate rapidly
increasing and changing information. This type of oversight
committee tends to be larger than the standard DMC which
typically comprises two physicians and one statistician, since a
wider range of expertise might be required and several regions
might need to be represented. In the case of adaptive designs or
complex platform trials, the DMC might be charged with extra
responsibilities beyond safety monitoring. For example, when
performing a formal interim analysis, the DMC might make
recommendations regarding treatment or subgroup selection,
as well as futility stopping or sample size re-estimation. Since
COVID-19 trials often use quickly observed endpoints, such
adaptations might still be meaningful, although the trials might
be quite short overall given rapid recruitment.
5.2. Regulatory Considerations
Basic regulatory requirements on adaptive designs to be used
in confirmatory study are laid down by the Food and Drug
Administration and EMA (European Medicines Agency 2007;
Food and Drug Administration 2019). In general, regulatory
concerns relate to the validity and robustness of the conclusions
to bemade with respect to a statement on the drug’s efficacy and
a thorough benefit risk assessment. In statistical terms, proper
Type I error control and unbiased effect estimates (or at least
minimization of bias) are of major concern for the primary
efficacy endpoint(s), whereas the potential lack of mature data
in trials with interim decision relate to the totality of the data
package. In addition to proper statistical methods to control
Type I error and bias in estimation, issues with the integrity
of the trial due to change in trial conduct following an interim
evaluation (and leading to inconsistency between stages) play a
major role in the assessment of the trial’s validity.
Referring to the specific pandemic setting, the request for
rapid decisions, investigation ofmultiple treatments, and poten-
tially changing controls could complicate the multiplicity issues
but the assessment of the trial’s validity remains an overriding
regulatory principle. In case the high medical need for effective
drugs in a pandemic situation leads to a different appraisal of
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Type I error rate control to make new treatments available as
fast as possible. It remains paramount to understand the trial’s
operating characteristics to ensure a fully informed regulatory
decision making.
In the specific setting of the COVID-19 pandemic with a
number of highly relevant risk factors, high heterogeneity with
respect to the severity of the disease and the onset of treatment,
a good characterization of the population that would profit
from treatment is crucial. Obviously, an extensive search for
the optimal subgroup and subsequent confirmation may not
be compatible with the need for rapid development. Regulatory
principles of subgroup selection are given in the EMA guideline
on the investigation of subgroups in confirmatory clinical trials
(European Medicines Agency 2019), to be applied in case a
positive effect has been established in the overall population but
plausible heterogeneity with respect to efficacy and severe side
effects asks for a refinement of the population.
6. Conclusions and Discussion
The examples provided in Section 2 give an indication of the
range of adaptive design approaches available, and show how
these methods have been embraced to advance research even
within the challenging setting of a pandemic. In all cases, the
objectives of the investigators were to choose an approach that
would yield scientifically rigorous results in as rapid a timeframe
as possible. The adaptive design framework provides sufficient
flexibility to enable trials of COVID-19 patients to be embedded
in ongoing trials, while MAMS and platform trial approaches
enable rapid evaluation of a number of potential treatments,
perhaps repurposed from other disease areas. Bayesian or fre-
quentist methods are available, and in each case can, provide
Type I error rate control, at least approximately, required in a
confirmatory clinical trial. It is also important that trials are
adequately powered, as control of the Type II error rate is
particularly relevant in the COVID-19 setting inwhich there are
no existing treatment options.
Although there can be no doubt that clinical research in the
setting of a pandemic raises a number of unique challenges, the
need for the evaluation of potential treatments in scientifically
rigorous randomized controlled clinical trials is as great as in
any other area of clinical research.
Whilst it is always desirable to conduct clinical trials of
new medical interventions in a timely fashion, faced with a
pandemic for which no vaccines or treatments are available, this
need is particularly acute, both because of the urgent need for
treatments and because of the limited time-window in which
large-scale research may be possible in a particular location, or
even globally.
Although trials that are unable to fully enroll in time to
inform a current outbreak may provide crucial data for future
outbreaks or may be analyzed in the context of a meta-analysis,
the need for clinical trials that can yield a conclusion, either pos-
itive or negative, as quickly as possible, makes adaptive design
methods particularly attractive, especially if they are flexible
enough to allow modifications to a trial in light of emerging
clinical knowledge and results from other ongoing or completed
clinical trials. It should be possible to suspend recruitment to
a trial during times when the disease is under control and to
resume if it re-emerges (Dean et al. 2020). The use of adaptive
platform designs, in particular for clinical trials in COVID-
19, has been proposed by a number of authors (Baucher and
Fontanarosa 2020) and, as illustrated by the examples given in
Section 2, a range of sequential and adaptive design methods
are being employed in ongoing clinical trials. Although not
a focus of this article, adaptive design methods also provide
valuable tools to allow formodification of trials in other diseases
necessitated by the COVID-19 pandemic (Kunz et al. 2020).
To yield timely results, it is clear that treatment trials should
start as soon as possible after an epidemic has begun. The time
limiting factor should be identification of candidate treatments,
and not the development of a statistical design. In the current
COVID-19 pandemic, although adaptive designs were used for
some trials, as indicated by the examples above, others which
could have benefited from such an approach will have been
planned with a fixed sample design because of the pressure
to start trials rapidly. Hence, research on trial designs that are
most suitable for the purposes of a pandemic should become
a research topic that goes beyond the actual case to be better
prepared for future pandemics.
A suitable design, or small suite of designs, should be
available on the shelf ready for use at any time. Debates
about trial design, including whether “best available care”
can vary amongst centers and whether Bayesian or frequen-
tist approaches are appropriate should be settled between
pandemics, and not reopened when they strike. It might be
supposed that such a generic approach is impossible and that the
design cannot be created without details of the natural history
of the disease or the specification of candidate treatments.
However, in almost all cases the primary patient responsewill be
status, a certain number ofDdays after randomization, classified
as dead/severely ill/moderately ill/recovered. The magnitude of
differences between treatments can be conveniently assessed
in terms of odds-ratios, and an odds-ratio of 2 is almost
always clinically important. A potential generic design has
been suggested by Whitehead and Horby (2017) that might be
a starting point in the search for a suitable vehicle. Perhaps
the COVID-19 experience will motivate the clinical trials
community to devise and agree upon such a generic design
once the current pandemic subsides. It should accommodate the
evaluation of multiple treatments compared with best available
care, with treatments entering the study as they are devised
and are approved for experimental use, and leaving as they are
demonstrated to be inferior to others. The design should be
adaptive and capable of being used across many sites, preferably
internationally.
Even if suitable trial designs are available, the planning and
conduct of clinical trials remains difficult. This is true for any
trial being conducted during a pandemic, when healthcare
resources are overstretched and the possibility of collecting
data from face-to-face assessments may be limited (Anker
et al. 2020). However, in trials focusing on the pandemic itself,
there are additional challenges in that the number of patients
likely to be affected, as well as the duration of the pandemic,
is unknown and may vary considerably across the globe. In
addition, pressures on healthcare systems mean that real-time
reporting of trial data is often difficult, reducing the information
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available at planned interim analyses. Given the importance
of solid evidence on the effectiveness of treatments, however,
we believe that every effort should be made to ensure that
logistical challenges in data collection and transfer do not
undermine otherwise high quality trials. For rigorous and quick
progress in evaluating treatments, there is a need for scientific
collaboration, and the necessary political cooperation to enable
and facilitate this. A multi-center trial can recruit patients
as quickly as possible by recruiting internationally, or from
different countries at different times as the pandemic progresses.
In a setting where scientific knowledge is rapidly changing and
research studies are being set up quickly, data sharing among
global scientific communities is key in allowing meta-analysis
methods, such as those described in Section 4.5, to be used.
Consequently, results fromanumber of studies can be combined
to provide robust evidence of treatment effectiveness, thus
preventing wastage of resources arising from the conduct of
multiple similar trials, each of which are individually too small
to yield definitive results.
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